Okay, let's tackle this question. The patient is a 45-year-old woman with easy bruising, headaches, and moderate splenomegaly. Her blood work shows a normal white cell count but a platelet count of 1000 x 10^3/cu mm, which is really high—thrombocytosis. The leucocyte alkaline phosphatase score is normal. The question is asking for the drug of choice.

First, I need to figure out the diagnosis. High platelets can be reactive (secondary) or primary (like in MPNs). Since the WBC is normal, maybe it's essential thrombocythemia (ET), which is a myeloproliferative neoplasm. Splenomegaly is common in ET. The LAP score is normal, which helps differentiate ET from other conditions like CML, where LAP is usually low. CML typically has low LAP and increased WBCs, so in this case, since WBC is normal and LAP is normal, ET is more likely.

The treatment for ET, especially in high-risk patients (like women over 60, or those with previous thrombosis or bleeding), is to reduce platelet count. The first-line treatment is hydroxyurea. Other options include anagrelide or interferon, but hydroxyurea is typically the drug of choice because it's effective and has a good safety profile. Aspirin is also used for antiplatelet effect but doesn't reduce platelet count.

So the correct answer is hydroxyurea. The options probably include hydroxyurea as one of them. Now, looking at the distractors: if any of the options are CML-related drugs like imatinib, that's not correct here. Also, if there's a drug for thrombocytopenia, that's wrong. The key points are the normal WBC and normal LAP score pointing to ET, and hydroxyurea as the first-line treatment.

**Core Concept**
This question tests the diagnosis and management of **essential thrombocythemia (ET)**, a myeloproliferative neoplasm characterized by elevated platelet counts, splenomegaly, and thrombotic/bleeding risks. Key differentials include reactive thrombocytosis and chronic myeloid leukemia (CML), with leucocyte alkaline phosphatase (LAP) score aiding differentiation.

**Why the Correct Answer is Right**
The patient has **platelet count of 1000×10³/μL** (severe thrombocytosis), splenomegaly, and **normal LAP score**, which excludes CML (low LAP) and reactive thrombocytosis (normal platelet count with secondary causes like infection). **Hydroxyurea** is the drug of choice for ET due to its efficacy in reducing platelet counts, minimizing thrombotic risks, and its role in splenomegaly reduction. It acts by inhibiting ribonucleotide reductase, suppressing marrow megakaryocyte proliferation.

**Why Each Wrong Option is Incorrect**
**Option A:** *Aspirin* is incorrect. While it reduces platelet aggregation, it does not lower platelet counts and is adjunctive, not first-line.
**Option

✓ Correct Answer: C. Anagrelide